Negative regulation of AKT activation by BRCA1

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10040-10044

  Xiang, Tao ^a   Ohashi, Amiko ^a   Huang, Yuping ^a   Pandita, Tej K ^a   Ludwig, Thomas ^b   Powell, Simon N ^a   Yang, Qin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL MUTANT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME ACTIVATION; FORKHEAD TRANSCRIPTION FACTORS; GENES, BRCA1; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; UBIQUITINATION;

EID: 57749115897     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3009     Document Type: Article

References (20)

1. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005;3:531-9.
2. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
3. McCoy ML, Mueller CR, Roskelley CD. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:72.
4. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003;302:639-42.
5. Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 2001;15:1188-93.
6. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003;302:636-9.
7. Bellacosa A, Kumar CC, Di CA, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
8. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
9. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
10. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-24.
11. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-7.
12. Miralem T, Avraham HK. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. Mol Cell Biol 2003;23:579-93.
13. 2/M phase of the cell cycle. Curr Biol 2002;12:919-24.
14. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-α activity. Mol Endocrinol 2007;21:1905-23.
15. Starita LM, Parvin JD. Substrates of the BRCA1-Dependent Ubiquitin Ligase. Cancer Biol Ther 2006;5:137-41.
16. Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 2002;12:86-91.
17. Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 2005;280:24498-505.
18. Rodriguez JA, Au WW, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res 2004;293:14-21.
19. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003;2003:RE5.
20. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.